Aluminum Toxicity Workup
- Author: Jose F Bernardo, MD, MPH, FASN; Chief Editor: Asim Tarabar, MD more...
Laboratory Studies
Generally, findings from an aluminum level blood test are unreliable, as most of the body's stores are bound in bone and tissue and are not reflected in the serum value. A deferoxamine infusion test can be performed but may take more than 48 hours to yield a result (see Medical Care). Deferoxamine liberates aluminum from tissues by chelating it and leads to an increased serum level compared with one taken prior to infusion. The combination of a baseline immunoreactive parathyroid hormone level of less than 200 mEq/mL and a change in serum aluminum value of 200 ng/mL after deferoxamine is 90% specific and has a positive predictive value of 85% for aluminum toxicity.
Aluminum excess has a direct effect on hematopoiesis and has been shown to induce anemia. Findings on peripheral smears in patients with aluminum toxicity include microcytic anemia (hypochromic, normochromic), anisocytosis, poikilocytosis, chromophilic cells, and basophilic stippling. Note that these are the same findings observed in patients with lead poisoning. Aluminum can also be found in bone marrow macrophages.
Imaging Studies
In radiographs, Looser zones (ie, lines of radiolucency parallel to the plane of growth in long bones) may be observed in severe cases, although they are more common with other causes of adult osteomalacia. Pathological fractures may also be observed. Bone scintigraphy shows a characteristic pattern in aluminum toxicity.
Other Tests
Bone biopsy from the iliac crest is frequently performed to determine the etiology of bone disease in patients on dialysis because renal osteodystrophy can be multifactorial (eg, osteomalacia, uremic bone disease, hyperparathyroidism, aluminum deposition). Histochemical staining for aluminum and determination of osteoid volume, bone turnover rate, and osteoblast/clast cell count are some of the methods used for subtyping the bone disease.
Procedures
Very few procedures are involved in the diagnosis of aluminum-related illness. Bone marrow biopsy is performed to distinguish between aluminum osteodystrophy and other causes of osteomalacia.
Histologic Findings
Histologic findings in aluminum-related osteomalacia reflect the decrease in mineralization of newly formed bone matrix.
- An increase in the surface covered by osteoid occurs, as does an increase in the osteoid seams.
- Osteoid volume and thickness also increase.
- In histologic sections stained with eosin, the areas of greater mineralization tend to appear violet or blue, whereas the osteoid seams appear pink.
Jiang HX, Chen LS, Zheng JG, Han S, Tang N, Smith BR. Aluminum-induced effects on Photosystem II photochemistry in citrus leaves assessed by the chlorophyll a fluorescence transient. Tree Physiol. Dec 2008;28(12):1863-71. [Medline].
Verstraeten SV, Aimo L, Oteiza PI. Aluminium and lead: molecular mechanisms of brain toxicity. Arch Toxicol. Nov 2008;82(11):789-802. [Medline].
Proudfoot AT. Aluminium and zinc phosphide poisoning. Clin Toxicol (Phila). Feb 2009;47(2):89-100. [Medline].
Brown RO, Morgan LM, Bhattacharya SK, Johnson PL, Minard G, Dickerson RN. Potential aluminum exposure from parenteral nutrition in patients with acute kidney injury. Ann Pharmacother. Oct 2008;42(10):1410-5. [Medline].
Trapp GA. Interactions of aluminum with cofactors, enzymes, and other proteins. Kidney Int Suppl. Feb 1986;18:S12-6. [Medline].
Andrasi E, Pali N, Molnar Z, Kosel S. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis. Aug 2005;7(4):273-84. [Medline].
Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. Jan 22 1976;294(4):184-8. [Medline].
Drago D, Cavaliere A, Mascetra N, et al. Aluminum modulates effects of beta amyloid(1-42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res. Oct 2008;11(5):861-71. [Medline].
Blaylock RL, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem. 2009;16(2):157-70. [Medline].
Bihaqi SW, Sharma M, Singh AP, Tiwari M. Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain. J Ethnopharmacol. Jul 30 2009;124(3):409-15. [Medline].
Mailloux RJ, Puiseux-Dao S, Appanna VD. Alpha-ketoglutarate abrogates the nuclear localization of HIF-1alpha in aluminum-exposed hepatocytes. Biochimie. Mar 2009;91(3):408-15. [Medline].
Bolt HM, Hengstler JG. Aluminium and lead toxicity revisited: mechanisms explaining the particular sensitivity of the brain to oxidative damage. Arch Toxicol. Nov 2008;82(11):787-8. [Medline].
Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses. Feb 2009;72(2):135-9. [Medline].
Shuchang H, Qiao N, Piye N, et al. Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci. 2008;26(6):467-73. [Medline]. [Full Text].
Gilbert-Barness E, Barness LA, Wolff J, Harding C. Aluminum toxicity. Arch Pediatr Adolesc Med. May 1998;152(5):511-2. [Medline].
Aspenstrom-Fagerlund B, Sundstrom B, Tallkvist J, Ilback NG, Glynn AW. Fatty acids increase paracellular absorption of aluminium across Caco-2 cell monolayers. Chem Biol Interact. Oct 7 2009;181(2):272-8. [Medline].
Balasubramanyam A, Sailaja N, Mahboob M, Rahman MF, Hussain SM, Grover P. In vivo genotoxicity assessment of aluminium oxide nanomaterials in rat peripheral blood cells using the comet assay and micronucleus test. Mutagenesis. May 2009;24(3):245-51. [Medline].
Bogris SL, Johal NS, Hussein I, Duffy PG, Mushtaq I. Is it safe to use aluminum in the treatment of pediatric hemorrhagic cystitis? A case discussion of aluminum intoxication and review of the literature. J Pediatr Hematol Oncol. Apr 2009;31(4):285-8. [Medline].
Riihimaki V, Valkonen S, Engstrom B, Tossavainen A, Mutanen P, Aitio A. Behavior of aluminum in aluminum welders and manufacturers of aluminum sulfate--impact on biological monitoring. Scand J Work Environ Health. Dec 2008;34(6):451-62. [Medline].
Vasudevaraju P, Govindaraju M, Palanisamy AP, Sambamurti K, Rao KS. Molecular toxicity of aluminium in relation to neurodegeneration. Indian J Med Res. Oct 2008;128(4):545-56. [Medline].
Lemire J, Mailloux R, Puiseux-Dao S, Appanna VD. Aluminum-induced defective mitochondrial metabolism perturbs cytoskeletal dynamics in human astrocytoma cells. J Neurosci Res. May 1 2009;87(6):1474-83. [Medline].
Hernandez G, Bollini A, Huarte M, et al. In vitro effect of aluminium upon erythrocyte membrane properties. Clin Hemorheol Microcirc. 2008;40(3):191-205. [Medline].
Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. May 2010;25(5):1604-8. [Medline].
Becaria A, Campbell A, Bondy SC. Aluminum as a toxicant. Toxicol Ind Health. Aug 2002;18(7):309-20. [Medline].
Bogle RG, Theron P, Brooks P, Dargan PI, Redhead J. Aluminium phosphide poisoning. Emerg Med J. Jan 2006;23(1):e3. [Medline]. [Full Text].
Campbell, Arezoo. The Potential role of aluminum in Alzheimer's disease. Nephrology Dialysis Transplantation. 2002;17 (suppl 2):17-20.
Candy JM, McArthur FK, Oakley AE, et al. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci. Feb 1992;107(2):210-8. [Medline].
Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant. 2002;17 Suppl 2:9-12. [Medline].
Chang TM, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet. Nov 5 1983;2(8358):1051-3. [Medline].
Chappard D, Insalaco P, Audran M. Aluminum osteodystrophy and celiac disease. Calcif Tissue Int. Jan 2004;74(1):122-3. [Medline].
Domingo JL. Reproductive and developmental toxicity of aluminum: a review. Neurotoxicol Teratol. Jul-Aug 1995;17(4):515-21. [Medline].
Drüeke TB, Lacour B, Touam M, et al. Effect of aluminum on hematopoiesis. Kidney Int Suppl. Feb 1986;18:S45-8. [Medline].
Friga V, Linos A, Linos DA. Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients?. Nephron. 1997;75(1):48-53. [Medline].
Graske A, Thuvander A, Johannisson A, et al. Influence of aluminium on the immune system--an experimental study on volunteers. Biometals. Jun 2000;13(2):123-33. [Medline].
Gupta VB, Anitha S, Hegde ML, et al. Aluminium in Alzheimer's disease: are we still at a crossroad?. Cell Mol Life Sci. Jan 2005;62(2):143-58. [Medline].
Hem JD. Geochemistry and aqueous chemistry of aluminum. Kidney Int Suppl. Feb 1986;18:S3-7. [Medline].
Key L, Bell N. Osteomalacia and disorders of vitamin D metabolism. In: Internal Medicine. 4th ed. 1994:1526-1527.
Kosier JH. Aluminum toxicity in the 1990s. ANNA J. Aug 1999;26(4):423-4. [Medline].
Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med. Jul 19 1984;311(3):140-4. [Medline].
Mayor GH, Sprague SM, Sanchez TV. Determinants of tissue aluminum concentration. Am J Kidney Dis. Nov 1981;1(3):141-5. [Medline].
McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med. Mar 1990;74(275):257-76. [Medline].
Priest ND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit. May 2004;6(5):375-403. [Medline].
Shea TB, Wheeler E, Jung C. Aluminum inhibits neurofilament assembly, cytoskeletal incorporation, and axonal transport. Dynamic nature of aluminum-induced perikaryal neurofilament accumulations as revealed by subunit turnover. Mol Chem Neuropathol. Sep-Dec 1997;32(1-3):17-39. [Medline].
Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium. Lancet. Apr 22 1978;1(8069):841-5. [Medline].
Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol. Apr 2001;88(4):159-67. [Medline].

